cancers-logo

Journal Browser

Journal Browser

Smart Nanotechnology for Drug Delivery in Cancer Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 30 August 2026 | Viewed by 1356

Special Issue Editor


E-Mail Website
Guest Editor
CNR NANOTEC—Istituto di Nanotecnologia, Via Monteroni, 73100 Lecce, Italy
Interests: nanomedicine; drug delivery; scanning force microscopy; cytomechanics; nanocarriers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanotechnology is a branch of science where nano-objects are developed for several uses and targeted applications, and also for medicine, opening a new, prospective field called nanomedicine (i.e., nanotechnology applied to medicine) for targeting drug delivery, for example, in cancer therapy. In this respect, smart nanotechnology tools such as nano-devices  (nano-channels, nano-chips or tailored nano-particles for farmaceutical delivery) may improve available (nano-)theranostic tools for treating (and may even diagnose) cancer. This Special Issue aims to collect contributions from the multidisciplinary scientific community in the field of drug delivery in order to develop and strengthen new nano-tools and ideas for improving cancer therapy in the near future. 

Prof. Dr. Stefano Leporatti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • drug delivery
  • cancer therapy
  • nanocarriers
  • nanoparticles
  • nano-devices
  • nano-channels

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 2958 KB  
Review
Therapeutic Potential of Peptides in Cancer Treatment: Focus on Peptide and Aptamer-Decorated Exosomes
by Prakash Gangadaran, Aswini Suresh Kumar, Kasinathan Kumaran, Kruthika Prakash, Sanjana Dhayalan, Ramya Lakshmi Rajendran, Vasanth Kanth Thasma Loganathbabu, Janani Balaji, Radhika Baskaran, Raksa Arun, Vanshikaa Karthikeyan, Sreyee Biswas, Chae Moon Hong, Kandasamy Nagarajan ArulJothi and Byeong-Cheol Ahn
Cancers 2026, 18(8), 1214; https://doi.org/10.3390/cancers18081214 - 10 Apr 2026
Viewed by 1066
Abstract
Traditional cancer therapies such as surgery, chemotherapy, and antibody-based treatments often face significant barriers, including systemic toxicity, a lack of selectivity, and the emergence of drug resistance. These issues demand innovative and targeted solutions. Peptide-based therapeutics have gained prominence for their ability to [...] Read more.
Traditional cancer therapies such as surgery, chemotherapy, and antibody-based treatments often face significant barriers, including systemic toxicity, a lack of selectivity, and the emergence of drug resistance. These issues demand innovative and targeted solutions. Peptide-based therapeutics have gained prominence for their ability to disrupt cancer pathways and facilitate targeted drug delivery, offering structural flexibility, precise targeting, and low immunogenicity with minimal effects on healthy tissues. Concurrently, aptamers, which are structured nucleic acid molecules capable of high-affinity molecular recognition, are being developed as both direct therapeutic agents and as targeting ligands for the improved delivery of anticancer drugs. Combining peptide and aptamer technologies with engineered exosomes provides a modular drug delivery system that enhances targeting specificity, stability, and the ability to cross complex biological barriers such as the blood–brain barrier. The emergence of peptide-decorated, aptamer-decorated exosomes represents a new frontier in precision oncology, promising highly selective, biocompatible, and tunable cancer therapies. Further advances are required to overcome challenges in pharmacokinetics, scalable production, and regulatory compliance, but ongoing bioengineering and nanotechnology research continues to accelerate the translation of these innovative strategies toward improved cancer diagnostics and treatment outcomes. This review discusses the synergistic integration of peptides and aptamers with exosome-based delivery systems, highlighting their current applications and future possibilities. Full article
(This article belongs to the Special Issue Smart Nanotechnology for Drug Delivery in Cancer Therapy)
Show Figures

Figure 1

Back to TopTop